Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Acute Pyelonephritis I: Introduction01:27

Acute Pyelonephritis I: Introduction

Pyelonephritis is a bacterial infection that primarily affects the renal parenchyma and collecting system, including the renal pelvis, tubules, and interstitial tissue of one or both kidneys. It can be classified as either acute—a sudden, severe infection—or chronic, which refers to long-term or recurrent kidney infections.The primary cause of acute pyelonephritis (APN) is bacterial infection, with Escherichia coli accounting for approximately 70-80% of cases. Other bacteria, such as Proteus,...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Inhibitors of Gram-positive Cell Wall Synthesis01:23

Inhibitors of Gram-positive Cell Wall Synthesis

Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Coaching junior faculty for the uncertainties of academic professional practice.

International journal of medical education·2021
Same author

Adjusted vs Total Body Weight-Based Dosing of Sedation and Analgesia Used in the Intensive Care Unit.

Hospital pharmacy·2020
Same author

Opioid Prescribing and Patient Satisfaction Scores Across Practice Types.

Journal of surgical orthopaedic advances·2020
Same author

Change in Management of Status Epilepticus With the Addition of Neurointensivist-Led Neurocritical Care Team at a Rural Academic Medical Center.

Hospital pharmacy·2018
Same author

Reduction in time to first action as a result of electronic alerts for early sepsis recognition.

Critical care nursing quarterly·2015
Same author

Evaluation of extended interval dosing aminoglycosides in the morbidly obese population.

Advances in pharmacological sciences·2013

Related Experiment Video

Updated: Jun 22, 2026

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
12:03

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Published on: April 18, 2019

Doripenem: position in clinical practice.

Harakh V Dedhia1, Richard McKnight

  • 1West Virginia University Health Science Center, 1 Medical Center Drive, Morgantown, WV 26506-9166, USA. hdedhia@hsc.wvu.edu

Expert Review of Anti-Infective Therapy
|June 3, 2009
PubMed
Summary

Doripenem is a potent carbapenem antibiotic effective against a wide range of bacteria, including Pseudomonas aeruginosa. Its favorable efficacy and safety profile position it as a key treatment for complicated infections.

Related Experiment Videos

Last Updated: Jun 22, 2026

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
12:03

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Published on: April 18, 2019

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Microbiology

Background:

  • Doripenem is a novel carbapenem antibiotic with broad-spectrum activity.
  • It demonstrates potent bactericidal effects against Gram-positive, anaerobic, and Gram-negative pathogens, including Pseudomonas aeruginosa.
  • Approved indications include complicated intra-abdominal and urinary tract infections.

Purpose of the Study:

  • To provide a comprehensive review of doripenem.
  • To discuss its mechanisms of resistance, clinical efficacy, and role in current medical practice.
  • To highlight its advantages over existing carbapenems.

Main Methods:

  • Literature review of doripenem's properties and clinical applications.
  • Analysis of in vitro and in vivo studies.
  • Comparison with other carbapenem agents.

Main Results:

  • Doripenem exhibits rapid bactericidal activity, with lower Minimum Inhibitory Concentration (MIC) values for Gram-negative bacteria compared to imipenem.
  • It has shown successful application in treating nosocomial and ventilator-associated pneumonia.
  • Favorable characteristics include stability against beta-lactamases, low adverse event potential, and potent activity against P. aeruginosa and Acinetobacter baumanni.

Conclusions:

  • Doripenem possesses attractive features, including broad-spectrum activity and favorable safety.
  • Its potent efficacy against challenging pathogens like P. aeruginosa and A. baumanni warrants consideration.
  • Doripenem holds potential as a preferred agent for treating severe bacterial infections, including hospital-acquired pneumonia.